These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 30140240)
1. Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Jones JL; Mateus CF; Malcolm RJ; Brady KT; Back SE Front Psychiatry; 2018; 9():277. PubMed ID: 30140240 [No Abstract] [Full Text] [Related]
2. Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. Coles AS; Knezevic D; George TP; Correll CU; Kane JM; Castle D Front Psychiatry; 2021; 12():808002. PubMed ID: 34975600 [No Abstract] [Full Text] [Related]
3. Potential role of N-acetylcysteine in the management of substance use disorders. McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756 [TBL] [Abstract][Full Text] [Related]
4. Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. Kelson M; Burnett JM; Matthews A; Juneja T Cureus; 2023 May; 15(5):e38498. PubMed ID: 37273364 [TBL] [Abstract][Full Text] [Related]
5. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Ivan Ezquerra-Romano I; Lawn W; Krupitsky E; Morgan CJA Neuropharmacology; 2018 Nov; 142():72-82. PubMed ID: 29339294 [TBL] [Abstract][Full Text] [Related]
7. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
8. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB; Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481 [TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis. Duailibi MS; Cordeiro Q; Brietzke E; Ribeiro M; LaRowe S; Berk M; Trevizol AP Am J Addict; 2017 Oct; 26(7):660-666. PubMed ID: 28898494 [TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Attention Biases in Opioid, Cannabis, Stimulant Use Disorders. Zhang M; Ying J; Wing T; Song G; Fung DSS; Smith H Int J Environ Res Public Health; 2018 Jun; 15(6):. PubMed ID: 29857586 [No Abstract] [Full Text] [Related]
11. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396 [TBL] [Abstract][Full Text] [Related]
12. Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders. Martins B; Rutland W; De Aquino JP; Kazer BL; Funaro M; Potenza MN; Angarita GA Curr Addict Rep; 2022; 9(4):647-659. PubMed ID: 35990796 [TBL] [Abstract][Full Text] [Related]
13. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Cooper K; Chatters R; Kaltenthaler E; Wong R Health Technol Assess; 2015 Jul; 19(56):1-130. PubMed ID: 26202542 [TBL] [Abstract][Full Text] [Related]
14. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Dakwar E; Nunes EV; Hart CL; Foltin RW; Mathew SJ; Carpenter KM; Choi CJJ; Basaraba CN; Pavlicova M; Levin FR Am J Psychiatry; 2019 Nov; 176(11):923-930. PubMed ID: 31230464 [TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of dual substance abuse and dependence. Kenna GA; Nielsen DM; Mello P; Schiesl A; Swift RM CNS Drugs; 2007; 21(3):213-37. PubMed ID: 17338593 [TBL] [Abstract][Full Text] [Related]
16. Ketamine and Cognitive Behavioral Therapy for Rapid Opioid Tapering With Sustained Opioid Abstinence: A Case Report and 1-Year Follow-up. Ocker AC; Shah NB; Schwenk ES; Witkowski TA; Cohen MJ; Viscusi ER Pain Pract; 2020 Jan; 20(1):95-100. PubMed ID: 31408575 [TBL] [Abstract][Full Text] [Related]
17. Psychosocial interventions for cannabis use disorder. Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547 [TBL] [Abstract][Full Text] [Related]
18. Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety. Rasmussen KG Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():218-24. PubMed ID: 25582770 [TBL] [Abstract][Full Text] [Related]
19. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Krystal JH; Madonick S; Perry E; Gueorguieva R; Brush L; Wray Y; Belger A; D'Souza DC Neuropsychopharmacology; 2006 Aug; 31(8):1793-800. PubMed ID: 16395307 [TBL] [Abstract][Full Text] [Related]